Interleukin-1
Testicular Neoplasms
National Cancer Institute (NCI)Phase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Testicular Neoplasms cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pembrolizumab Nasser Hanna, M.D. | Phase 2 | CCC |
Sgn-Alpv Seagen Inc. | Phase 1 | CC |
Same molecule, other indications
Interleukin-1 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →